MX389806B - Ligandos opioides kappa de heteroaril fenoxi benzamida - Google Patents

Ligandos opioides kappa de heteroaril fenoxi benzamida

Info

Publication number
MX389806B
MX389806B MX2019006220A MX2019006220A MX389806B MX 389806 B MX389806 B MX 389806B MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 389806 B MX389806 B MX 389806B
Authority
MX
Mexico
Prior art keywords
sub
disorder
heteroaryl
kappa opioid
phenoxy benzamide
Prior art date
Application number
MX2019006220A
Other languages
English (en)
Spanish (es)
Other versions
MX2019006220A (es
Inventor
Bruce Nelsen Rogers
Danica Antonia Rankic
Gregory Wayne Kauffman
Justin Ian Montgomery
Kapildev Kashmirilal Arora
Matthew Francis Dunn
Michael Aaron Brodney
Michael Eric Green
Natasha Mariam Kablaoui
Patrick Robert Verhoest
Scot Richard Mente
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2019006220A publication Critical patent/MX2019006220A/es
Publication of MX389806B publication Critical patent/MX389806B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2019006220A 2016-11-28 2017-11-27 Ligandos opioides kappa de heteroaril fenoxi benzamida MX389806B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662426980P 2016-11-28 2016-11-28
US201762576435P 2017-10-24 2017-10-24
US201762585016P 2017-11-13 2017-11-13
PCT/IB2017/057418 WO2018096510A1 (en) 2016-11-28 2017-11-27 Heteroarylphenoxy benzamide kappa opioid ligands

Publications (2)

Publication Number Publication Date
MX2019006220A MX2019006220A (es) 2019-10-07
MX389806B true MX389806B (es) 2025-03-20

Family

ID=60782279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006220A MX389806B (es) 2016-11-28 2017-11-27 Ligandos opioides kappa de heteroaril fenoxi benzamida

Country Status (18)

Country Link
US (1) US10316021B2 (enExample)
EP (1) EP3544972B8 (enExample)
JP (1) JP7051853B2 (enExample)
CN (1) CN110234638B (enExample)
AU (1) AU2017365123B2 (enExample)
DK (1) DK3544972T3 (enExample)
ES (1) ES2947293T3 (enExample)
FI (1) FI3544972T3 (enExample)
HR (1) HRP20230518T1 (enExample)
HU (1) HUE061945T2 (enExample)
IL (1) IL266962B (enExample)
MX (1) MX389806B (enExample)
PH (1) PH12019501172A1 (enExample)
PL (1) PL3544972T3 (enExample)
PT (1) PT3544972T (enExample)
RS (1) RS64258B1 (enExample)
TW (1) TWI720272B (enExample)
WO (1) WO2018096510A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018154118A2 (en) * 2017-02-24 2018-08-30 Reinmueller Viktoria Novel aromatic compounds
US11591289B2 (en) 2017-02-24 2023-02-28 Xeniopro GmbH Aromatic compounds
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
TWI807291B (zh) * 2020-04-05 2023-07-01 美商輝瑞大藥廠 用於治療covid-19之化合物及方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
IL315415A (en) 2022-03-07 2024-11-01 Janssen Pharmaceuticals Inc The compositions containing eticarpant
KR20240156409A (ko) * 2022-03-07 2024-10-29 얀센 파마슈티칼즈, 인코포레이티드 주요 우울 장애 치료에 사용을 위한 아티카프란트의 다형 형태
IL315411A (en) * 2022-03-07 2024-11-01 Janssen Pharmaceuticals Inc Pure forms of crystalline eticarpant
PE20251585A1 (es) * 2022-10-12 2025-06-16 Adama Makhteshim Ltd Proceso para la preparacion de derivados de aminopiridazina

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2000017162A1 (en) * 1998-09-21 2000-03-30 Takeda Chemical Industries, Ltd. Novel thiol derivatives, process for producing the same and utilization thereof
JP2000159747A (ja) 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
IT1303737B1 (it) 1998-11-11 2001-02-23 Smithkline Beecham Spa Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
SI2208727T1 (sl) 2002-09-19 2012-11-30 Lilly Co Eli Diaril etri kot antagonisti opioidnega receptorja
US7365209B2 (en) 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
CN1753884A (zh) 2003-03-07 2006-03-29 伊莱利利公司 阿片类受体拮抗剂
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
CN101120055B (zh) 2005-02-18 2014-07-23 日本曹达株式会社 有机无机复合体
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
PL2001456T3 (pl) 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
CR11559A (es) 2008-03-25 2010-10-20 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
US8048895B2 (en) 2008-04-18 2011-11-01 Research Triangle Institute Kappa opioid receptor ligands
SG10201510696RA (en) 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
US8609696B2 (en) 2008-12-18 2013-12-17 Boehringer Ingelheim International Gmbh Serotonin 5-HT2B receptor inhibitors
HN2010001319A (es) 2009-01-26 2013-01-15 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
US20150274657A1 (en) 2012-10-02 2015-10-01 Merck Patent Gmbh Pyrrolidines
WO2015109080A1 (en) 2014-01-15 2015-07-23 Research Triangle Institute Kappa-opioid receptor selective opioid receptor antagonists
US10118896B2 (en) 2014-11-26 2018-11-06 University Of Kansas Antagonists of the kappa opioid receptor

Also Published As

Publication number Publication date
AU2017365123A1 (en) 2019-07-11
HRP20230518T1 (hr) 2023-08-04
JP2019535799A (ja) 2019-12-12
US20180148432A1 (en) 2018-05-31
AU2017365123B2 (en) 2022-02-17
CN110234638B (zh) 2022-10-21
PH12019501172A1 (en) 2019-12-11
MX2019006220A (es) 2019-10-07
IL266962A (en) 2019-07-31
CA3045242A1 (en) 2018-05-31
US10316021B2 (en) 2019-06-11
WO2018096510A1 (en) 2018-05-31
EP3544972B8 (en) 2023-06-07
TW201831460A (zh) 2018-09-01
CN110234638A (zh) 2019-09-13
JP7051853B2 (ja) 2022-04-11
DK3544972T3 (da) 2023-05-30
ES2947293T3 (es) 2023-08-04
NZ754862A (en) 2024-11-29
PT3544972T (pt) 2023-06-20
IL266962B (en) 2022-02-01
TWI720272B (zh) 2021-03-01
PL3544972T3 (pl) 2023-07-24
RS64258B1 (sr) 2023-07-31
HUE061945T2 (hu) 2023-09-28
EP3544972B1 (en) 2023-04-26
FI3544972T3 (fi) 2023-06-02
EP3544972A1 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
MX389806B (es) Ligandos opioides kappa de heteroaril fenoxi benzamida
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12020551304A1 (en) Novel crystalline forms
PH12015501771A1 (en) Pest controlling composition and use thereof
WO2017204445A3 (ko) Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AU2018231032A8 (en) JAK inhibitors containing a 4-membered heterocyclic amide
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
CR20200617A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MY196809A (en) (),()-unsaturated amide compound
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
PH12019500822B1 (en) Crystalline forms of eravacycline
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
MX2021006692A (es) Proceso mejorado para preparar ozanimod.
PH12021550390A1 (en) Fungicidal nitroanilino substituted pyrazoles
MX2020001724A (es) Compuestos de pirazol-isoxazolina plaguicidas y parasiticidas.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
MX389613B (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.